New Study: RenovaCare SkinGun™ Ultra-Gently Sprays Human Stem Cells to Achieve ‘Gold-Standard’ Viability for Skin Regeneration

New York & Pittsburgh – May 3, 2016 – RenovaCare, Inc., (OTCQB: RCAR), a developer of novel medical grade liquid spray devices and patented CellMist™ and SkinGun™ technologies*, today announced favorable outcomes from laboratory studies conducted by Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité – Universitätsmedizin Berlin, one of the…

RenovaCare, Inc. Completes Engineering, Research, and Studies Required to File 510(k) Submission to the FDA for its Novel Medical-Grade Liquid Spray Device

New York & Pittsburgh – April 12, 2016 – RenovaCare, Inc., a developer of novel medical grade liquid spray devices and patented CellMist™ and SkinGun™ technologies* for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced that the company has successfully completed the engineering, studies, and associated efforts…